• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option.布加替尼用于初治的间变性淋巴瘤激酶（ALK）阳性晚期非小细胞肺癌：一种有效但仍有缺陷的选择。
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S378-S382. doi: 10.21037/tlcr.2019.04.15.
2
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.布加替尼在间变性淋巴瘤激酶重排的非小细胞肺癌和其他恶性肿瘤中的活性和安全性：一项单臂、开放标签、1/2 期试验。
Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.
3
Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.非小细胞肺癌中间变性淋巴瘤激酶抑制剂的临床药代动力学。
Clin Pharmacokinet. 2019 Apr;58(4):403-420. doi: 10.1007/s40262-018-0689-7.
4
An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.评估布加替尼作为非小细胞肺癌有前途的治疗选择。
Expert Opin Pharmacother. 2019 Sep;20(13):1551-1561. doi: 10.1080/14656566.2019.1643839. Epub 2019 Jul 22.
5
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.布加替尼，一种间变性淋巴瘤激酶抑制剂，可消除ALK阳性神经母细胞瘤细胞、果蝇和小鼠中的活性并抑制其生长。
Oncotarget. 2016 May 17;7(20):29011-22. doi: 10.18632/oncotarget.8508.
6
Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.布加替尼用于治疗ALK阳性的晚期非小细胞肺癌患者。
Drugs Today (Barc). 2017 Aug;53(8):435-446. doi: 10.1358/dot.2017.53.8.2676119.
7
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).布加替尼在序贯 ALK 抑制剂治疗后的 ALK 阳性晚期非小细胞肺癌患者中的应用：一项多中心真实世界研究（BRIGALK 研究）。
Lung Cancer. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010. Epub 2019 Aug 14.
8
Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.布加替尼：新一代针对非小细胞肺癌的 ALK 抑制剂。
Curr Probl Cancer. 2019 Dec;43(6):100477. doi: 10.1016/j.currproblcancer.2019.03.005. Epub 2019 May 6.
9
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.非小细胞肺癌的靶向治疗：聚焦于ALK/ROS1酪氨酸激酶抑制剂
Expert Rev Anticancer Ther. 2018 Jan;18(1):71-80. doi: 10.1080/14737140.2018.1412260. Epub 2017 Dec 6.
10
Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.克唑替尼治疗期间晚期间变性淋巴瘤激酶重排非小细胞肺癌患者中枢神经系统转移的管理。
Clin Lung Cancer. 2019 Nov;20(6):e631-e637. doi: 10.1016/j.cllc.2019.06.013. Epub 2019 Jun 18.

引用本文的文献

1
Primary resistance to ALK inhibitors in -rearranged pleural metastatic lung adenocarcinoma: a case report.间变性淋巴瘤激酶（ALK）重排的胸膜转移性肺腺癌对ALK抑制剂的原发性耐药：一例报告
Transl Lung Cancer Res. 2023 Nov 30;12(11):2342-2346. doi: 10.21037/tlcr-23-482. Epub 2023 Nov 28.
2
[Early Onset Pulmonary Events and Management Strategies during the Treatment of 
ALK Positive NSCLC Patients with Brigatinib].[布加替尼治疗ALK阳性非小细胞肺癌患者期间的早期肺部事件及管理策略]
Zhongguo Fei Ai Za Zhi. 2023 Apr 20;26(4):281-290. doi: 10.3779/j.issn.1009-3419.2023.101.12.

本文引用的文献

1
Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.晚期间变性淋巴瘤激酶阳性非小细胞肺癌中洛拉替尼的耐药突变与疗效。
J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.
2
Brigatinib for -positive metastatic non-small-cell lung cancer: design, development and place in therapy.布加替尼用于ALK阳性转移性非小细胞肺癌：设计、研发及治疗地位
Drug Des Devel Ther. 2019 Feb 8;13:569-580. doi: 10.2147/DDDT.S147499. eCollection 2019.
3
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。
Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.
4
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.布加替尼与克唑替尼用于治疗间变性淋巴瘤激酶阳性的非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.
5
Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.在日本，对间变性淋巴瘤激酶重排的转移性非小细胞肺癌患者进行阿来替尼预处理后的塞瑞替尼的 II 期研究：ASCEND-9。
Cancer Sci. 2018 Sep;109(9):2863-2872. doi: 10.1111/cas.13721. Epub 2018 Jul 25.
6
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.布加替尼治疗阿来替尼耐药的间变性淋巴瘤激酶阳性非小细胞肺癌患者的效果。
J Thorac Oncol. 2018 Oct;13(10):1530-1538. doi: 10.1016/j.jtho.2018.06.005. Epub 2018 Jun 20.
7
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.针对 ALK 阳性非小细胞肺癌的精准医学：超越克唑替尼。
Med Oncol. 2018 Apr 17;35(5):72. doi: 10.1007/s12032-018-1133-4.
8
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.阿来替尼对比克唑替尼用于未经治疗的 ALK 阳性非小细胞肺癌。
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
9
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.布加替尼治疗克唑替尼耐药间变性淋巴瘤激酶阳性非小细胞肺癌患者的随机、多中心 II 期临床试验。
J Clin Oncol. 2017 Aug 1;35(22):2490-2498. doi: 10.1200/JCO.2016.71.5904. Epub 2017 May 5.
10
Optimal management of ALK-positive NSCLC progressing on crizotinib.克唑替尼治疗进展的ALK阳性非小细胞肺癌的优化管理。
Lung Cancer. 2017 Apr;106:58-66. doi: 10.1016/j.lungcan.2017.02.003. Epub 2017 Feb 6.

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option.

作者信息

Ricciuti Biagio, Lamberti Giuseppe, Roila Fausto, Metro Giulio

机构信息

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.

Department of Experimental, Diagnostic and Specialty Medicine, Policlinico di Sant'Orsola University Hospital, Bologna, Italy.

出版信息

Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S378-S382. doi: 10.21037/tlcr.2019.04.15.

DOI:10.21037/tlcr.2019.04.15
PMID:32038919
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6987338/
Abstract
摘要